 |
| Robert Herring, Gastroenterologist |
Dr. Robert W. Herring Jr. MD is a board certified gastroenterologist specializing in diagnosis and treatments of gastrointestinal and liver problems. He received his Doctor of Medicine degree from the University of Tennessee, Memphis in 1980. Dr. Herring has extensive experience in Internal Medicine and Gastroenterology. He earned his Gastroenterology and Hepatology Fellowship at Johns Hopkins University in 1985. Dr. Herring is a Fellow of the American College of Gastroenterology.
EDUCATIONAL BACKGROUND
John Overton High School, Nashville, Tennessee, 1972 GPA 4.00, Valedictorian
Bachelor of Science, Majors in Biology and Chemistry (Double), Birmingham-Southern College, Birmingham, Alabama, 1976 GPA 3.81, magna cum laude. Phi Beta Kappa Scholastic Honorary Fraternity
Doctor of Medicine, University of Tennessee, Memphis, Tennessee, 1980, GPA 3.62, cum laude. Alpha Omega Alpha Scholastic Honorary Fraternity
Residency in Internal Medicine, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina, 1980-1983
Fellowship in Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland, 1983-1985
AWARDS AND HONORS
Americas Top Gastroenterologists Consumers Research Council of America, 2012
Recognized as Doctor of Excellence and a Top Gastroenterologist of Tennessee International Association of Healthcare Professionals, 2013
PUBLICATIONS & PRESENTATIONS
Herring, R.W., Potter, J.J., and Mezey, E. (1986). Effect of acute alcohol administration on erythrocyte aldehyde dehydrogenase activity in man. Alcoholism: Clinical and Experimental Research, 10 (Supplement 6): 41S-45S.
Pruitt, Ron E., M.D., Gremillion, Daniel E., M.D., Herring, Robert W., Jr., M.D., Bailey, Allan, M.D., Faust, Thomas W., M.D., Potter, Michele, P.A., Long, Karen M., RN, MSN, CFNP, Nashville Gastrointestinal Specialists and Medical Research Institute, Nashville, Tennessee. “Oral 5-ASA (Asacol) in the Treatment of Mild to Moderate Ulcerative Colitis (UC): The Nashville Experience.” Journal of Tennessee Medical Association, 84: 237, 1991.
Pruitt, R.E., M.D., Gremillion, Daniel, M.D., Herring, Robert W., Jr., M.D., Bailey, Allan, M.D., Faust, Thomas W., M.D., Long, Karen M., RN, MSN, CFNP. “Safety and Tolerance of Oral 5-ASA (Asacol) in the Treatment of Ulcerative Colitis and Crohn’s Disease: Results of the US Multicenter Open-Label Study.” Gastroenterology, 100: A 241, 1991.
Pruitt, R.E., Gremillion, D., Herring, R., Bailey, A.H., Faust, T.W., and Long, K. “Safety and Tolerance of Oral 5-ASA (Asacol ) in the Treatment of Ulcerative Colitis and Crohn’s Disease: Results of the US Multicenter Open-Label Study.” American Gastroenterological Association, American Association for the Study of Liver Diseases. May 19-22, 1991. New Orleans, Louisiana.
Jensen, D., Wedemeyer, H., Herring Jr., R, Ferenci, P., Mang, M., Zeuzem, S., Rodriguez-Torres, M., Bzowej, N., Pockros, P., Vierling, J., Ipe, D., Hill, George. “High Rates of Early Viral Response, Promising Safety Profile and Lack of Resistance-Related Breakthrough in HCV GT 1/4 Patients Treated With RG7128 Plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 Interim Analysis from the PROPEL Study. Poster Presentation. American Association for the Study of Liver Diseases, Annual Meeting, 2010.
DR Nelson, S Zeuzem, P Andreone, P Ferenci, R. Herring, DM Jensen, P Marcellin, PJ Pockros, M. Rodriguez-Torres, L. Rossaro, VK Rustgi, T. Sepe, M Sulkowki, IR Thomason, E Yoshida, A Chan, G Hill. “Balapiravir Plus Peginterferon alfa-2a (40KD) and Ribavirin for the Treatment of Chronic Hepatitis C Genotype 1: Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.” Gastroenterology, Manuscript. October 5, 2010.
Wedemeyer, H., Jensen, D., Herring, Jr., R., Ferenci, P., Mang-Ming, M., Zeuzem, S., Rodriguez-Torres, M., Bzowej, N., Pockros, P., Vierling, J., Ipe, D., Thommes, J. “Efficacy and Safety of Mericitabine (MCB) in Combination with PegIFNɑ-2A/RBV in G1/4 Treatment Naïve RCV Patients: Final Analysis From the PROPEL Study.” Poster Presentation. European Association for the Study of Liver Disease, Annual Meeting, 2011, Stockholm, Sweden.
M. Sulkowski, M. Rodriguez-Torres, E Lawitz, M. Shiffman, S Pol, R Herring, John McHutchison, Phil Pang, Diana Brainard, D Wyles, F Habersetzer. “High Sustained Viral Response in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated for 12 Weeks with an Interferon-Free All-Oral Quad Regimen: Interim Results.” Poster Presentation. European Association for the Study of Liver Disease, April, 2012.
I. Jacobson, E. Lawitz, J. Lalezari, I. Crespo, M. Davis, T. Hassanein, M. DeMicco, S. Arora, N. Gitlin, R. Herring, D.R. Nelson, J.K. Anderson, R.H. Hyland. “GS-7977 400 mg QD Safety and Tolerability in the Over 500 Patients Treated for 12 Weeks”. Poster Presentation. 47th Annual European Association for the Study of Liver Disease, April, 2012.
M. Sulkowski, M. Rodriguez-Torres, E. Lawitz, M. Shiffman, S. Pol, R. Herring, J.G. McHutchison, P.S. Pang, K.A. Wong, B. Massetto, Y. Zhu, D.M. Brainerd, D. Wyles, F. Habersetzer. “Interim Sustained Virologic Response Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated for 12 or 24 Weeks with an Interferon-Free All-Oral Quad Regimen”. Poster Presentation. 47th Annual European Association for the Study of Liver Disease, April, 2012.
M. Sulkowski, M. Rodriguez-Torres, E. Lawitz, M. Shiffman, S. Pol, R. Herring, J.G. McHutchison, B. Massetto, D.M. Brainerd, P.S. Pang, D. Wyles, F. Habersetzer. “Complete SVR4 Rates in Treatment-Naïve HCV Genotype 1a and 1b Patients Treated with an Interferon-Free All-Oral Quad Regimen”. Poster Presentation. American Association for the Study of Liver Diseases, Annual Meeting, 2012.
Andrew J. Muir, Robert Herring, Jr., Aasim Sheikh, Michael Ryan, Vinod Rustgi, Viktor Ankoma-Sey, Joanne Fabrycki, James Freddo, James Hui, Mingjun Huang, Dharaben Patel, Lisa Robarge, Heather Robison, Guangwei Yang, Yongsen Zhao, Milind Deshpande, Hetal S. Kocinksy, Robert Brennan. “A Single Direct-Acting Anti-Viral Agent, ACH-3102, in Combination with Ribavirin is Able to Achieve SVR8 in Subjects with Genotype 1b Chronic Hepatitis C Infection”. Abstract, EASL, 2013.
Click the below link for more information
http://www.herringmd.com
No comments:
Post a Comment